127 results about "Solid cancer" patented technology

The present disclosure relates to methods of treating or preventing cancer (e.g., advanced solid cancer) using Compound No. 1: (Compound No. 1) or a pharmaceutically acceptable salt thereof. The present disclosure also relates to pharmaceutical compositions and pharmaceutical kits suitable for the treatment or prevention.

Provided herein are methods, dosage regimens, and administration of an antibody drug conjugate (ADC) for treating cancer. More specifically, the cancer is advanced or metastatic solid cancer.

Provided is a method for treating solid cancer using an anti-CD47 antibody.

There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.

A room temperature injectable thermo-responsive hydrogel comprises a P407 poloxamer base hydrogel, chitosan, 2-Hydroxypropyl β-cyclodextrin and genipin. The chitosan and genipin form an interpenetrating scaffold within the hydrogel in which the chitosan is crosslinked with genipin. Chemotherapeutic drugs can be added to the hydrogel singly or in combination in effective amounts without any loss of thermo-responsiveness in the hydrogel. Therapeutic use of the thermo-responsive hydrogel in the intratumoural treatment of solid cancer is also described.

This article provides information on multi-chain chimeric peptides and their use in the treatment of unresectable, advanced, recurrent and / or metastatic solid tumors or unresectable, advanced, recurrent and / or metastatic solid cancers.

An injectable liquid containing bioactive molecules released from a powder comprising a neo-synthesized extracellular matrix for use in the treatment or prevention of cancer, in particular in the local treatment of solid tumors.

The present invention relates to a method of establishing a prediction regarding the development of a type of solid cancer in an individual, comprising: (i) collecting a biological sample that includes lymphocytes of said individual, (ii) sequencing, using NGS techniques, the mRNA associated with the V(D)J regions of the TCRs of the lymphocytes collected in the previous step, (iii) removing from the TOR repertoire obtained in the previous step the TOR sequences that are specific to other diseases than said solid cancer, (iv) using artificial intelligence algorithms to compute a predictive score for the probability that said TOR repertoire is specific for said type of cancer and (v) based on said predictive score determining the probability of said individual of developing said type of solid cancer.

The present disclosure provides a group of aromatic (e.g., pyridinyl, pyrimidinyl, pyrazinyl, or phenyl) diamidine analogs and pharmaceutically acceptable salts that are useful for treating a proliferative disease. The proliferative disease may include solid cancer or blood cancer. Compositions, methods of synthesizing the same and methods for treating various cancer using the analogs are disclosed herein. The present disclosure also provides pharmaceutical formulations comprising at least one of the compounds with a pharmaceutically acceptable carrier, diluent or excipient therefor.

To provide a therapeutic agent for PARP inhibitor-resistant cancer.SOLUTION: The present invention relates to a pharmaceutical composition for treating or preventing a solid cancer patient having resistance to a PARP inhibitor, and the pharmaceutical composition according to the present invention can effectively reduce the size of a tumor in a patient having resistance to a PARP inhibitor.SELECTED DRAWING: Figure 4

Methods of improving PD-1 based immunotherapy in a subject suffering from a solid cancer, comprising decreasing bone morphogenetic protein 1 (BMP1) levels or function in T cells or in a tumor microenvironment (TME) or extracellular matrix (ECM) of the solid cancer are provided. Methods of treating a solid cancer comprising administering a PD-1 based immunotherapy and decreasing BMP1 levels or function in T cells or a TME or ECM of the solid cancer are also provided. Antibody drug conjugates comprising an anti-PDl blocking antibody and a BMP1 inhibiting small molecule or antibody or antigen binding fragment thereof small molecule inhibitor and pharmaceutical compositions for use in the methods of the invention are also provided.

The present invention provides a use of paclitaxel cationic liposomes in the manufacture of a medicament for treating terminal solid cancer, a use of paclitaxel cationic liposomes and a systemic therapeutic agent in the manufacture of a medicament for treating terminal solid cancer, and a method for treating terminal solid cancer, in which a therapeutically effective amount of paclitaxel cationic liposomes is administered to a patient with terminal solid cancer, or a therapeutically effective amount of paclitaxel cationic liposomes and a systemic therapeutic agent is administered to a patient with terminal solid cancer.

Provided is a method for treating solid cancer using an anti-CD47 antibody.

The present disclosure relates to antibodies against beta-catenin and formulations comprising the antibodies. The present disclosure also relates to the use of beta-catenin antibodies and formulations in therapy, in particular in the treatment of solid cancer.

The present invention relates to a use of a substance comprising point-mutated FoxM1 protein and peptide for inhibiting growth, migration and invasion of cancer cells. In addition, it relates to a use of a substance comprising point-mutated FoxM1 protein and peptide for inhibiting malignancy in a tumor microenvironment by inhibiting polarization into tumor-associated macrophages in a tumor microenvironment. It relates to a use as an apoptotic inducer using the action of sensitively inhibiting cancer cell death in metastatic cancer cells as well as general solid cancers.

The present invention relates to a pharmaceutical composition for prevention or treatment of solid cancer comprising an epidithiodioxopiperazine derivative compound based on a parent structure comprising an intramolecular disulfide bridge in an epidithiodioxopiperazine ring or a pharmaceutically acceptable salt thereof as an active ingredient.

The disclosure provides methods of treating cancer, such as an estrogen receptor negative (ER–) solid cancer or estrogen receptor-low (ERlow) solid cancer in a patient. The method may include administering to the patient an effective amount of lasofoxifene, or a pharmaceutically acceptable salt or functional derivative thereof.

The present disclosure provides a group of aromatic (e.g., pyridinyl, pyrimidinyl, pyrazinyl, or phenyl) diamidine analogs and pharmaceutically acceptable salts that are useful for treating a proliferative disease. The proliferative disease may include solid cancer or blood cancer. Compositions, methods of synthesizing the same and methods for treating various cancer using the analogs are disclosed herein. The present disclosure also provides pharmaceutical formulations comprising at least one of the compounds with a pharmaceutically acceptable carrier, diluent or excipient therefor.

The present invention relates to: an affinity that specifically binds to the extracellular domain of CD137; a protein complex comprising the affinity and an antibody or an antigen-binding fragment thereof that specifically binds to a protein on the surface of cancer cells; and a pharmaceutical composition for preventing or treating cancer, comprising the same as an active ingredient. When using the affinity that specifically binds to CD137 according to the present invention, it is possible to develop a protein complex that specifically binds to antigens on the surfaces of various cancer cells while specifically binding to T cells, and thus can be effectively used in the prevention or treatment of leukemia and solid cancers.

The present disclosure provides methods, compositions, uses, and kits for treatment of solid cancer (e.g., urothelial cancer (UC), head and neck squamous cell carcinoma (HNSCC), cervical cancer (CC), endometrial carcinoma (EC), or triple-negative breast cancer (TNBC)) using anti-human Nectin-4 therapeutics.

Provided is a means to predict the anticancer therapeutic efficacy of 1-((5-(1R)-1-fluoroethyl)-1,3,4-oxadiazol-yl)methyl)-6-(4-methoxypyrrolo[2,1-f][1,2,4]triazin-5-yl)-2-methyl-1H-imidazo[4,5-b]pyridine or a derivative thereof in solid cancer and thereby specifying a subject who will be the most benefitted from treatment with the compound and treatment with the compound in combination with another drug and / or another therapy. As a biomarker for predicting therapeutic response to the compound, a genetic character predicted to impart sensitivity to CLK inhibition is used.

To provide anti-CD38 antibodies that may be used in the treatment of cancer, particularly solid and hematological cancers.SOLUTION: Provided is an anti-CD38 antibody having a particular sequence, or antigen-binding fragment thereof, the anti-CD38 antibody or antigen-binding fragment thereof exhibiting antibody-dependent cell-mediated cytotoxicity (ADCC) activity against CD38+ target cells, exhibiting no complement dependent cytotoxicity (CDC) or reduced CDC activity against CD38+ target cells as compared to Daratumumab under the same or substantially the same conditions, and inducing immune effector cell activation.SELECTED DRAWING: Figure 20

The present invention relates to anti-cancer viruses that co-express complement regulatory proteins CD55 and CD59. Since the anti-cancer virus of the present invention can maintain its curative effect even when intravenously injected, the anti-cancer virus can also be applied to the treatment of various solid cancers and metastatic cancers in addition to superficial solid cancers. Furthermore, the anti-cancer virus of the present invention obtains resistance to attacks of an in-vivo complement system by expressing complement regulatory protein on the surface of the virus, thereby being stable in blood and maintaining stable anti-cancer activity during intravenous injection, thereby reducing the application amount of the virus to reduce the side effects of anti-cancer drugs as much as possible. Therefore, the anti-cancer virus of the present invention can be used for preventing or treating cancer.

The present invention relates to the treatment of diseases associated with inflammation including solid cancers. More particularly, certain methods relate to the administration (e.g., intravenously) of polyhedrin protein (PODS) crystals for the delivery of one or more therapeutic proteins. This enables targeted release of low doses of the therapeutic protein at sites of the disease.

The present invention consists in combining low dose intestinal radiation (ILDR) with immunotherapy or other antineoplastic treatments, in the ideal context of intestinal presence or prevalence of Christensenellaceae family members, especially for solid cancers at an advanced stage (refractory to first line chemo or immunotherapy). The invention also pertains to a bacterial composition,e.g. comprising Chistensenella bacteria, for use in the treatment of cancer in a patient, in combination with intestinal low dose radiotherapy (ILDR) and an antineoplastic treatment.

The invention provides improved compositions and methods for the treatment of solid cancers.

Disclosed herein are methods and compositions for inhibiting the interaction of a multiple endocrine cancer suppressor protein with an MLL protein. In particular, the present application provides compositions and methods for inhibiting the interaction of multiple endocrine cancer suppressor proteins with MLL1, MLL2, and MLL-fusion cancer proteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases that depend on MLL1, MLL2, MLL fusion protein and / or multiple endocrine cancer suppressor protein activity.

The present invention relates to a total dry extract of elderberry (Sambucus nigra) and to its use as an anti-cancer drug both preventive and for treatment. In particular, the invention relates to an extract comprising active ingredients capable of effectively and synergistically combatting the growth of cancer cells totally regressing, in particular solid cancers.

The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and / or menin.

To provide safe and effective, non-toxic pentamidine analogs that exhibit increased organ targeting that may allow for oncological clinical development designed for specific types of cancer.SOLUTION: The present disclosure provides a group of aromatic (e.g., pyridinyl, pyrimidinyl, pyrazinyl, or phenyl) diamidine analogs and pharmaceutically acceptable salts that are useful for treating a proliferative disease. The proliferative disease may include solid cancer or blood cancer. Compositions, methods of synthesizing the same and methods for treating various cancer using the analogs are disclosed herein. The present disclosure also provides pharmaceutical formulations comprising at least one of the compounds with a pharmaceutically acceptable carrier, diluent or excipient therefor.SELECTED DRAWING: Figure 1